{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:46:54Z","timestamp":1772578014089,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.clbc.2011.02.001","type":"journal-article","created":{"date-parts":[[2011,5,23]],"date-time":"2011-05-23T00:30:48Z","timestamp":1306110648000},"page":"252-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With\/Without Bevacizumab"],"prefix":"10.1016","volume":"11","author":[{"given":"Nuttapong","family":"Ngamphaiboon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Frustino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen B.","family":"Kossoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey L.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2011.02.001_bib1","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib2","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clbc.2011.02.001_bib4","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clbc.2011.02.001_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.clbc.2011.02.001_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0765.2010.01306.x","article-title":"Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6","volume":"46","author":"Tipton","year":"2011","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.clbc.2011.02.001_bib8","doi-asserted-by":"crossref","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-09-0426","article-title":"High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties","volume":"15","author":"Pozzi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2011.02.001_bib9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0049-0172(94)90054-X","article-title":"Pamidronate stimulates recruitment and decreases longevity of osteoclast nuclei in mice","volume":"23","author":"Holt","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clbc.2011.02.001_bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ar.a.10092","article-title":"Cellular mechanism of inhibition of osteoclastic resorption of bone and calcified cartilage by long-term pamidronate administration in ovariectomized mature rats","volume":"274","author":"Mayahara","year":"2003","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"10.1016\/j.clbc.2011.02.001_bib11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S8756-3282(01)00655-X","volume":"30","author":"Van Beek","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.clbc.2011.02.001_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.joms.2009.01.007","article-title":"The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data","volume":"67","author":"Allen","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clbc.2011.02.001_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00008505-199500440-00002","article-title":"Remodeling dynamics of bone supporting rigidly fixed titanium implants: a histomorphometric comparison in four species including humans","volume":"4","author":"Garetto","year":"1995","journal-title":"Implant Dent"},{"key":"10.1016\/j.clbc.2011.02.001_bib14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1359\/jbmr.1997.12.4.498","article-title":"Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanisms of bone loss","volume":"12","author":"Han","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2011.02.001_bib15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ar.a.20396","article-title":"Remodeling dynamics in the alveolar process in skeletally mature dogs","volume":"288","author":"Huja","year":"2006","journal-title":"Anat Rec A Discov Mol Cell Evol Biol"},{"key":"10.1016\/j.clbc.2011.02.001_bib16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.joms.2008.01.038","article-title":"Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment","volume":"66","author":"Allen","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clbc.2011.02.001_bib17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ncponc0520","article-title":"Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates","volume":"3","author":"Santini","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib18","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000313787","article-title":"Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws","volume":"124","author":"Allegra","year":"2010","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.clbc.2011.02.001_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro","volume":"15","author":"Ziebart","year":"2011","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.clbc.2011.02.001_bib20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2141.2008.07504.x","article-title":"Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis","volume":"144","author":"Scheper","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clbc.2011.02.001_bib21","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2011.02.001_bib22","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2011.02.001_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2011.02.001_bib24","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2011.02.001_bib25","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib26","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.clbc.2011.02.001_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clbc.2011.02.001_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl","key":"10.1016\/j.clbc.2011.02.001_bib30","article-title":"Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and\/or bevacizumab-treated patients (pts) at Memorial Sloan-Kettering Cancer Center (MSKCC)","volume":"26","author":"McArthur","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib31","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clbc.2011.02.001_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.breast.2009.07.001","article-title":"Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment","volume":"18","author":"Fehm","year":"2009","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2011.02.001_bib33","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdp233","article-title":"Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study","volume":"20","author":"Van Cutsem","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib34","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1634\/theoncologist.2009-0155","article-title":"Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials","volume":"15","author":"Geiger-Gritsch","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2011.02.001_bib35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients","volume":"67","author":"Lazarovici","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clbc.2011.02.001_bib36","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.joms.2009.04.051","article-title":"Bisphosphonate-related osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients","volume":"67","author":"Thumbigere-Math","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clbc.2011.02.001_bib37","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2011.02.001_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091100019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152682091100019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:04:17Z","timestamp":1761512657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152682091100019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S152682091100019X"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2011.02.001","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteonecrosis of The Jaw: Dental Outcomes in Metastatic Breast Cancer Patients Treated With Bisphosphonates With\/Without Bevacizumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2011.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}